Clinical cancer research : an official journal of the American Association for Cancer Research
A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.
Sebastian Medina, Naoto Tokuyama, Kamal Hammouda, Tilak Pathak, Tuomas Mirtti, Pingfu Fu, Shilpa Gupta, Priti Lal, Howard M Sandler, Rohann Correa, Susan Chafe, Amit Shah, Jason A Efstathiou, Karen Hoffman, Michael Straza
Published: 202510.1158/1078-0432.CCR-25-3327
Abstract
PURPOSE: Docetaxel improves survival in metastatic hormone-sensitive prostate cancer (mHSPC) and high-risk localized disease, but benefits vary substantially among patients. Without predictive biomarkers, clinicians cannot identify patients who will…
Preview only. Read the full abstract at the source